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Resveratrol enhances polyubiquitination-mediated
degradation in prostate cancer cells
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ABSTRACT
Although androgen deprivation therapy (ADT) serves as the primary treatment
option for localized or metastatic prostate cancer, most cases eventually develop
into castration-resistant prostate cancer (CRPC). However, androgen receptor
(AR) continues to be functional in CRPC through various mechanisms, including
the development of AR splicing variants, especially ARV7. Since it lacks the ligand
binding domain but retains the intact DNA binding domain, ARV7 is constitutively
active, which makes ARV7-positive prostate cancer responsive to neither abiraterone
nor enzalutamide. In this study, we explored the effect of resveratrol on ARV7
transcriptional activity and the potential for development of resveratrol as a treatment
for ARV7-positive prostate cancer. First, we ectopically expressed ARV7 in PC3 cells,
an AR-negative prostate cancer cell line, and demonstrated that resveratrol is capable
of inhibiting ARV7 transcriptional activity by downregulating ARV7 protein levels. Of
note, resveratrol does not affect the mRNA levels of ARV7 nor its nuclear translocation.
Next, we demonstrated that resveratrol is capable of downregulating the levels of the
endogenously expressed ARV7 as well as AR target gene mRNAs in 22RV1 prostate
cancer cells. Mechanistically, resveratrol downregulates ARV7 by enhancing ARV7
polyubiquitination and subsequent proteasome-mediated degradation. These findings
suggest that resveratrol could be a potential treatment for ARV7-positive CPRC.

INTRODUCTION

metastasized prostate cancers. However, a quarter of these
patients suffer relapse of the disease and most prostate
cancers eventually become castration resistant (CRPC)
with tumor recurrence and metastasis within a period of
6 months to 3 years [1, 5, 6]. Furthermore, in the less
developed countries, most prostate cancers are diagnosed
at advanced stages [7]. Therefore, prostate cancer is a big
burden for both developed and developing countries, and
thus understanding of the mechanisms underlying prostate
cancer development and progression as well as developing

Prostate cancer is one of the most frequently
diagnosed cancers and the second leading cause of
cancer-related death in men in the United States [1, 2].
In addition, the incidence of prostate cancer is increasing
significantly due to the effects of the western lifestyle and
the increase of the aging population [3, 4]. Androgendeprivation therapy (ADT) is the first line of defense, and
most of the time, an effective treatment for localized and
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efficacious therapies for prostate cancer, especially CRPC,
is urgently needed.
The androgen/androgen receptor (AR) axis
plays crucial roles in both normal prostate function
and the development of prostate diseases including
prostate cancer. Depleting androgen or inhibiting AR
transcriptional activity has been proven to be effective in
prostate cancer treatment. Multiple lines of evidence show
that re-establishment of functional AR transcriptional
activity is a critical event in the emergence of CRPC.
Both abiraterone and enzalutamide are currently the best
agents for CYP17 and AR inhibition, respectively. These
drugs either individually or in combination can extend the
survival of patients with CRPC. However, development of
resistance to these drugs is inevitable [8, 9] for a subgroup
of CRPC expressing different AR variant characterized
with the loss of the c-terminal domain but maintaining
both N-terminal transcriptional domain and the ligand
binding domain [10, 11]. Reports from different groups
showed that prostate cancer cells expressing constitutively
active AR splicing variants respond to neither of these
reagents [8, 12, 13].
More recent data suggest that among the 22 AR
slicing variants identified so far [14], ARV7 is not only
the most prevalent [15, 16] but also most relevant to the
development of CRPC [17]. ARV7 is generated from
alternative splicing of the third intron of the AR premRNA, which creates a cryptic exon and leads to the
formation of a truncated AR with a stretch of 16 extra
amino acids unique for this particular variant. Although
ARV7 is expressed in the presence of AR-full length
mRNA and most of the time co-expressed with full-length
AR, results from different labs showed not only that the
positivity but also the intensity of ARV7 are enhanced
by hormonal therapies. For example, Antonarakis et al
[18] reported that ARV7 was detected in 55% of patients
who had received prior abiraterone versus those who had
not; enzalutamide treatment increased ARV7 expression
from 15% to 50%, suggesting that ADT can enhance the
expression of ARV7 to a certain degree. More importantly,
clinical responses were inversely correlated with ARV7
expression: 68% of ARV7-negative patients showed PSA
response when treated with abiraterone comparing to
0% response in the ARV7-positive group. When treated
with enzalutamide, 53% and 0% of patients showed
PSA response in the ARV7-negative and ARV7-positive
groups, respectively [17]. Therefore, the identification and
application of agents capable of targeting ARV7 would be
a valuable strategy in treatment of CRPC.
Resveratrol (RSV, 3,4′,5-trihydroxystilbene) is
one of the well-documented reagents in prostate cancer
chemoprevention [19]. Chemically, RSV is a polyphenol
transhydroxystilbene found at high levels in grapes
and red wines [20]. Animal studies have demonstrated
that RSV is rapidly absorbed by the gut and distributed
into different tissues [21, 22]. Since the first reported
www.impactjournals.com/oncotarget

cancer chemopreventive effects of RSV in 1997 [23],
both epidemiological and case-controlled studies have
demonstrated that RSV and/or consumption of high RSVcontaining foods and drinks can reduce prostate cancer
incidences [24]. There are multiple lines of evidence
shown that RSV exerts its effects on prostate cancer in
an AR-dependent manner [25–27] through involvement
of the regulation of AR expression and function [28, 29].
It has been well established that RSV downregulates the
expressions of both AR and AR target genes [30–32].
Harada et al. reported that RSV represses AR target gene
expression, at least partially, by enhancing AR degradation
in a time- and dose-dependent manner [33]. We have
demonstrated that RSV regulates AR target gene expression
by repressing AR transcriptional activity without affecting
AR nuclear translocation nor DNA binding [34].
In this report, we showed that RSV is capable of
inhibiting ARV7-mediated transcription of AR target
genes in prostate cancer cells by downregulating the
protein levels of both ectopically and endogenously
expressed ARV7 without affecting either mRNA levels nor
its nuclear translocation. Mechanistically, RSV enhances
polyubiquitination and subsequent degradation of ARV7
in a proteasome-dependent manner.

RESULTS
Ectopically expressed ARV7 is capable of
upregulating PSA in PC-3 cells
Since it has been reported that the transcriptional
activity of ARV7 is partially dependent on the expression
of full-length AR [35], we wanted to determine if ARV7
is capable of regulating AR target gene expression in a
full-length AR-free prostate cancer cellular environment.
To do so, we decided to ectopically express ARV7 in
PC3 cells, a prostate cancer cell line expressing neither
full-length AR nor ARV7, by transiently transfection of
plasmids expressing ARV7. To confirm that PC3 cells are
ARV7- and PSA-negative, we conducted RT-PCR with
mRNAs obtained from two prostate cancer cell lines PC3
and LNCaP. Since LNCaP cells were known AR-positive
prostate cancer cells and express readily detectable PSA,
we chose to use LNCaP cells as the positive control.
As expected, both full-length AR and PSA were readily
detectable by RT-PCR but with undetectable level of
ARV7 in LNCaP cells. However, none of the fulllength AR, PSA or ARV7 was expressed in PC3 cells
(Figure 1A). Then, PC3 cells were transiently transfected
with or without plasmid expressing ARV7 followed by
RT-PCR (Figure 1B) and western blot (Figure 1C) assays.
As shown in Figure 1B and 1C, ARV7 was successfully
transfected and expressed in PC3 cells, as evidenced
by the fact that ARV7 mRNA (Figure 1B) and protein
(Figure 1C) were only detected in the cells transfected
with ARV7-expressing plasmid. In addition, both RT2
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PCR (Figure 1D) and quantitative PCR (Figure 1E)
demonstrated that the ectopically expressed ARV7 is
capable of upregulating AR target gene PSA. These data
also suggest that ARV7 can function without the fulllength AR.

AR’s nuclear translocation can be used as a strategy in
repressing AR transcriptional regulation. We wanted to
determine if RSV represses ARV7 transcriptional activity
by inhibiting its nuclear translocation. To this end, we
treated the PC3 cells transfected with ARV7-expressing
plasmid with or without 100 µM RSV for 24 hours and
conducted immunostaining with antibody against the
N-terminus of AR, which is able to recognize both fulllength AR and ARV7. Immunostaining of LNCaP cells
treated with the synthesized androgen R1881 serves as
experimental control. As shown in Figure 3, although
RSV treatment reduced the total ARV7 levels dramatically
(consistent with changes observed in Figure 2), the
expressed ARV7 was mainly found in the nuclei whether
the cells were treated with or without RSV. These data
suggest that RSV inhibits ARV7 transcriptional activity
by downregulating ARV7 protein levels without affecting
its nuclear translocation. In addition, since ARV7 was
ectopically expressed in PC3 cells without the full-length
AR, we also conclude that the nuclear translocation of
ARV7, at least for the ectopically expressed form, is
independent of the full-length AR.

RSV inhibits ARV7 transcriptional activity by
downregulating its protein levels
To determine if RSV can inhibit ARV7
transcriptional activity, we treated PC3 cells transfected
with ARV7-expressing plasmid with different
concentrations of RSV for 24 hours. Total mRNAs were
purified and the PSA levels serving as an indicator of the
ARV7 transcriptional activity were estimated by RT-PCR
(Figure 2A) and qPCR (Figure 2B). Figure 2A and 2B
show that ARV7 transcriptional activity is inhibited by
RSV in a dose-dependent manner. Next, we conducted
RT-PCR and western blot assays to determine if RSV
downregulates ARV7 transcriptional activity by repressing
its mRNA or protein levels. As shown in Figure 2C, ARV7
mRNA levels were not affected by RSV treatment but
protein levels were downregulated by RSV in a dosedependent manner (Figure 2D). These data collectively
demonstrated that RSV is capable of inhibiting ARV7
transcriptional activity in a dose-dependent manner and
mechanistically downregulating ARV7 protein levels
without affecting mRNA level.

RSV downregulates endogenously expressed
ARV7 without affecting full-length AR
After demonstrating RSV’s effects on the
ectopically expressed ARV7, we wanted to determine
if RSV has similar effects on ARV7 endogenously
expressed in prostate cancer cells. We chose to use the
22RV1 cell line because it represents the CRPC prostate
cancer cells and both full-length AR and ARV7 were
expressed endogenously in these cells. First, we treated
22RV1 cells with increasing concentrations of RSV
for 24 hours, and the cell viabilities were estimated by

RSV does not affect ARV7 nuclear translocation
Upon the binding of androgens, the full-length
AR translocates to the nucleus from the cytoplasm and
interacts with the androgen responsive element (ARE) to
regulate AR target gene expression. Therefore, targeting

Figure 1: Ectopically expressed ARV7 in PC-3 cells is capable of upregulating PSA. (A) RT-PCR with mRNAs from both

LNCaP and PC-3 cells with primers specific for full-length AR, ARV7, PSA and GAPDH. (B–C) PC-3 cells were transiently transfected
with or without plasmid expressing ARV7, and RT-PCR (B) or WB (C) was conducted. (D–E) RT-PCR (D) or qPCR (E) was conducted
with mRNAs from PC-3 cells transfected with or without ARV7.
www.impactjournals.com/oncotarget
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Figure 2: RSV inhibits ARV7 transcriptional activity by downregulating ARV7 protein levels. PC-3 cells were transiently
transfected with plasmid expressing ARV7 and treated with different concentrations (0–100 µM) of RSV for 24 hours. Both RT-PCR (A)
and qPCR (B) were conducted to estimate the effect of RSV on the mRNA levels of PSA; RT-PCR and WB were conducted to estimate the
levels of ARV7 mRNA (C) and protein (D).

Figure 3: PC-3 cells were transiently transfected with plasmid expressing ARV7 and treated with or without RSV
for 24 hours. LNCaP cells were treated with 10 nM R1881 for 24 hours. Immunostaining was conducted to determine the subcellular
localizations of AR and ARV7. Scale bar: 100 µm.

www.impactjournals.com/oncotarget
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counting the number of live cells. As shown in Figure 4A,
RSV is capable of inhibiting 22RV1 cell growth in a
dose-dependent manner. Then, we conducted RT-PCR
to estimate RSV’s effects on the mRNA levels of PSA
and ARV7. Figure 4B (RT-PCR) and 4C (qPCR) show
that RSV is able to dose-dependently repress PSA levels
without affecting the levels of ARV7 mRNA. In addition,
we have conducted RT-PCR on another three potential
ARV7 target genes (UBE2C, TMPRSS2 and FKBP51) to
estimate RSV’s effect on ARV7 transcriptional activity.
Supplementary Figure 1 show that the mRNA levels of all
of them were downregulated by RSV. However, western
blotting assays demonstrated that the ARV7 protein levels
were dose-dependently downregulated by RSV (Figure 4D
and 4E). Of note, the protein levels of the full-length AR
were not affected by RSV treatment in these cells. These
data suggest that resveratrol is capable of downregulating
ARV7 protein levels without affecting the full-length AR
protein level in 22RV1 cells.

RSV for different time periods. Cells were collected at
different time points and both full-length AR and ARV7
protein levels were determined by western blotting assays
with antibody against either AR or actin. As shown in
Figure 5A and 5B, ARV7 protein levels decreased in a
time-dependent manner in either treatment but the fulllength AR and actin levels were relatively unchanged
during the observed period. However, compared to the
cells treated with cyclohexmide alone, RSV appears to
be able to reduce ARV7 stability because ARV7 levels
decreased dramatically in the cells treated with the
combination of RSV and cyclohexamide. The intensities
of the protein bands were estimated by ImageJ program
and the estimated full-length AR and ARV7 levels were
normalized with actin, and the normalized levels in both
treatments were plotted (Figure 5C). It is clear that RSV
is capable of enhancing ARV7 degradation by reducing
the half-life of ARV7 from about 4 hours (CHX only) to
2 hours (CHX+RSV). Interestingly, the protein levels of
full-length AR were not affected significantly.

RSV enhances ARV7 protein degradation in
prostate cancer cells

RSV enhances ARV7 polyubiquitination and
subsequent degradation

Next, we wanted to understand the mechanism
in RSV-induced ARV7 protein downregulation. To
this end, we treated 22RV1 cells with 50µM/mL of
cyclohexmide alone or in combination with 100µM

To test if RSV enhances ARV7 degradation through
the polyubiquitination-mediated proteasome pathway,
we treated the 22RV1 cells with RSV or MG132 alone

Figure 4: RSV inhibits prostate cancer growth and downregulates ARV7 in 22RV1 cells without affecting full-length
AR. 22RV1 cells were treated with different concentrations (0–100 µM of RSV for 24 hours and the number of viable cells were estimated
through cell counting (A). The mRNA levels of PSA and ARV7 were estimated by RT-PCR (B) and q-PCR (C). The protein levels of ARV7
and full-length AR were estimated by western blotting assays (D and E).

www.impactjournals.com/oncotarget
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or in combination for 24 hours. ARV7 protein levels
were estimated by western blot assays with p53 as the
experimental control. As shown in Figure 6A the p53
level was elevated when the cells were treated with either
RSV or MG132 alone or in combination. However, the
ARV7 levels were not significantly affected under the
same conditions. In addition, treatment of the cells with
RSV alone reduced the ARV7 level as seen previously.
These data suggest that RSV’s effect on ARV7 degradation
is either not through the polyubiquitination-mediated
pathway or somehow different from the mechanism
used by p53 degradation. To determine if RSV affects
polyubiquitination in general, we conducted western
blot assay using antibody against ubiquitin. As shown in
Figure 6B, although the overall levels of polyubiquinated
proteins in these cells were not affected by RSV treatment
alone (lane 2), RSV is capable of enhancing the MG132
inhibited protein degradation (lane 3). As expected,
when the cells were treated with MG132 alone the
polyubiquitinated protein levels were elevated (lane 4).
These data suggest that RSV is capable of enhancing
protein ubiquitination but the polyubiquitinated proteins
were quickly degraded in the absence of MG132.
We then treated 22RV1 cells with RSV or MG132
alone or in combination for 24 hours and conducted
immunoprecipitation with antibody against AR
N-terminus which is able to recognize both full-length
AR and ARV7. Normal IgG was used as a negative
control. The precipitated proteins were analyzed by
western blotting assays. As shown in Figure 6C, ARV7
was readily detectable in the inputs, and both the fulllength AR and ARV7 were successfully precipitated by
the specific antibody; the normal IgG only nonspecifically
precipitated some background levels of proteins. Of note,
either RSV or MG132 alone or in combination failed to
affect ARV7 levels significantly. However, when the same

blot was stripped and re-probed with antibody against
ubiquitin (Figure 6D), we found that MG132 alone was
able to increase the levels of polyubiquitinated ARV7
and this effect was synergized with RSV. Nevertheless,
the levels of polyubiquitinated ARV7 in the cells treated
with RSV alone were about the same as those of the
control. These data altogether demonstrate that RSV
is capable of enhancing ARV7 polyubiquitination but
the polyubiqitinated ARV7 is quickly degraded (RSV
alone) by the proteasome system because inhibition of
proteasome-mediated protein degradation by MG132
leads to the accumulation of polyubiquitinated ARV7
(RSV+MG132).
Given the fact that 22RV1 cells express both fulllength AR and ARV7 and there are potential interactions
between them.
In order to demonstrate that RSV mediates
ARV7 degradation by enhancing polyubiquitination,
similar experiments were done with the exogenously
expressed ARV7 in PC3 cells. First, we conducted
immunoprecipitation of the exogenously expressed ARV7
in PC3 cells treated with RSV and MG132 alone or in
combination (Supplementary Figure 2) and found that RSV
downregulated ARV7, MG132 failed to counteract RSV
effect. Supplementary Figure 3 shows that, similar to was
on endogenously expressed ARV7, the polyubiquitination
of the exogenously expressed ARV7 is enhanced by RSV.
To further that RSV effect on ARV7 degradation is through
polyubiquitination pathway, we estimated the levels of
ARV7 and overall protein ubiquitination in 22RV1 cells
treated with either RSV or PYR-41 (an inhibitor of the
E1 enzyme in the ubiquitination pathway) alone or in
combination. Supplementary Figure 4A shows that the
total protein levels were comparable among the differently
treated samples. However, WB results (Supplementary
Figure 4B) indicate that RSV is capable of enhancing

Figure 5: Effect of RSV on ARV7 protein degradation. 22RV1 cells were cultured in growth media with 50 nM CHX along (A) or

in combination with 100 µM RSV (B) and collected at different time points (0–8 h). Western blotting assays were conducted with antibodies
against ARV7 and actin. The intensities of the protein bands were estimated by Image-J and normalized with that of actin and plotted (C).
www.impactjournals.com/oncotarget
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polyubiquitinated (comparing lanes 1 and 2) and the E1
enzyme inhibitor PYR-41 effectively repressed RSVinduced poly-ubiquitination (comparing lanes 2 and 3).

cells express neither full-length AR nor AR target PSA
(Figure 1), this enabled us to determine the effects of
RSV on the ectopically expressed ARV7 in a prostate
cancer cellular environment but without the effects of
the endogenously expressed ARs. We demonstrated that
RSV is capable of downregulating both ARV7 protein
levels and its transcriptional activity without affecting its
mRNA levels (Figure 2). Note, the transcription of ARV7
in this system was controlled by the CMV promoter and
since the level of ARV7 mRNA is not affected by RSV,
it suggests that RSV-mediated downregulation of ARV7
protein level is likely not through an effect on ARV7
mRNA stability. The same findings were confirmed with
the endogenously expressed ARV7 in 22RV1 prostate
cancer cells (Figure 4). Although there are some reports
suggesting that a functional ARV7 depends on the
existence of the full-length AR [35], our results suggest
that ARV7 can regulate AR target gene PSA in a fulllength AR-independent manner. In addition, even though it
does not contain the canonical nuclear translocation signal,
ARV7 is mainly expressed in the nuclei of the prostate
cancer cells, and RSV appears not to affect ARV7 nuclear
translocation (Figure 3).
It has been well documented that RSV can inhibit
the function of the full-length AR through different
mechanisms, including enhancement of AR degradation.
However, we found that RSV is capable of downregulating
ARV7 protein levels without affecting the full-length AR
in 22RV1 cells. This observation leads us to speculate that
RSV exerts its degradation effects on the full-length AR

DISCUSSION
Given the fact that [1] ARV7 positivity strongly
correlates with both CRPC status and poor prognoses for
prostate cancer patients diagnosed at late stages [36], and [2]
ARV7-positive prostate cancers have proven to be resistant
to almost all currently available prostate cancer drugs and
therapies [37–39], either reducing the level or inhibiting the
activity of ARV7 would be plausible therapeutic strategies
for ARV7-positive CRPC. Based on this, we evaluated if
RSV is able to affect ARV7 and found that RSV is not only
capable of downregulating the levels of ARV7 but also
of repressing the expression of its target genes in prostate
cancer cells. Based on our observations, we proposed a
working model (Figure 7) to explain the RSV-enhanced
polyubiquitination and subsequent degradation of ARV7
in prostate cancer cells. Without the presence of protein
degradation inhibitor MG132, RSV-enhanced ARV7
polyubiqitination is followed by quick degradation. In the
presence of MG132, ARV7 is polyubiquitinated but fails
to be degraded and therefore the level of polyubiquitinated
ARV7 is increased. However, under either condition, the
non-ubiquitinated ARV7 is reduced by RSV.
In order to determine if RSV can target ARV7
specifically, we first tested the effects of RSV on the
ectopically expressed ARV7 in PC3 cells. Since PC3

Figure 6: Effect of RSV on polyubiquitination in prostate cancer cells. (A–B) 22RV1 cells were treated with or without RSV
and MG132 for 24 hours. WB was conducted to estimate the levels of ARV7, P53 (A) and ubiquitinated proteins (B). Lysates were used for
immunoprecipitation with antibodies against AR or nonspecific IgG, and the precipitated proteins were analyzed by WB with antibodies
against AR (C), ubiquitin or tubulin (D).
www.impactjournals.com/oncotarget
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and ARV7 through different mechanisms. This speculation
has been further substantiated by the fact that the half-life
of ARV7 but not that of the full-length AR was shortened
by RSV in 22RV1 cells. Given the fact that ARV7 has a
sequence identical to the full length AR except for the
extra 16 amino acids at its C-terminus, we speculate that
this short sequence in itself or together with part of the
rest of ARV7 plays an essential role in RSV-mediated
ARV7 degradation. In addition, this short sequence may
also be responsible for the nuclear translocation of ARV7.
However, bioinformatics analyses of this short sequence
(unpublished data) failed to identify any motif particularly
related to protein degradation or nuclear translocation.
It has been reported recently that by screening a drug
library containing about 1120 FDA-approved chemicals
with an unbiased strategy, the well-studied anti-helminthic
drug niclosamide was found to be able to repress ARV7
recruitment to the PSA promoter, resulting in decreased PSA
transcription. Further exploration found that niclosamide
utilizes a proteasome-dependent pathway to degrade ARV7
protein which resulted in decreased ARV7 protein level but
without affecting its mRNA level [40]. Therefore, the authors
suggest that niclosamide alone or in combination with other
anti-cancer drugs could be used for the treatment of CRPC.
However, niclosamide has been used as an anti-helmithic
drug with multiple issues unrelated to prostate cancer.
Therefore, treating prostate cancers with niclosamide may
lead to some undesirable side effects, and thus making this
drug a relatively unattractive therapeutic option for CRPC.
Although RSV downregulates ARV7 in a similar manner as
niclosamide, RSV has not shown any side-effects but with
multiple beneficial effects on skin disorders, type II diabetes,
cardiovascular diseases, and obesity [41]. Therefore, RSV
appears to be superior to niclosamide in downregulating

ARV7. However, the drawback to RSV as a potential
therapeutic option is its relatively low bioavailability
in human tissues [42]. On the other hand, pterostilbene
(PTER) is a structural analog of RSV with greater tissue
bioavailability than RSV [43]. Our preliminary data suggest
that PTER functions similarly to RSV in regard to ARV7
(unpublished data) and once this is fully confirmed, PTER
could be an even better drug to target ARV7 in CRPC.
In addition, there are other strategies targeting the levels
of ARV7. For example, Jin et al. found that NF-kB can
increase ARV7 expression in prostate cancer cells. They
also found that when NF-kB signaling pathway is blocked,
both ARV7 mRNA and protein levels were down-regulated.
Furthermore, blocking NF-kB signaling makes CRPC cells
become ADT-responsive [44]. Therefore, a combination of
therapies targeting ARV7 mRNA levels (such as blocking
NF-kB) with RSV and/or PTER could be more efficacious
in the treatment of ARV7-positive CRPC.
In summary, we demonstrated that RSV is capable
of downregulating both ectopically and endogenously
expressed ARV7 in prostate cancer cells without affecting
the mRNA levels or the nuclear translocation of ARV7.
Mechanistically, RSV enhances ARV7 polyubiquitination
and subsequent proteasome-mediated degradation. These
observations suggest that RSV possesses a great potential
to become a treatment for ARV7-positive CPRC.

MATERIALS AND METHODS
Cell lines and chemicals
DMSO, resveratrol (RSV), MG132, R1881 were
all purchased from Sigma-Aldrich (St. Louis, MO).
Resveratrol stock solution (1 mM) was made by dissolving

Figure 7: Model of RSV enhancing polyubiquitination-mediated ARV7 degradation.
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RSV in DMSO and stored at −20°C in the dark. Antibodies
against both full-length AR and ARV7 (N-20), ß-tubulin,
GAPDH ubiquitin and normal rabbit IgG were purchased
from Santa Cruz Biotechnologies and all stored at 4°C.
The ARV7 expressing plasmid was a kind gift from Dr.
Lu’s lab (The James Buchanan Brady Urological Institute
and Department of Urology, The Johns Hopkins School
of, Baltimore, MD 21287, USA). LNCaP, 22RV1 and
PC3 cells were obtained from American Type Culture
Collection (ATCC). PC3 cells were cultured in Ham’s
F-12 with L-glutamine, 10% premium FBS, and 1%
Antibiotic-Antimycotic. LNCap and 22RV1 cells were
maintained in RPMI 1640 medium supplemented with
10% (wt/vol) fetal bovine serum (FBS) and 1% antibiotics
at 37°C under 5% CO2.

For qPCRs, the SYBR Premix Ex Taq II (Tli RNase H
Plus) Kit was used per manufacturer’s recommendation.

Preparation of lysates and western blot
Whole cell lysates were obtained using the nuclear
extract kit (Active Motif, California) according the
manufacturer’s instructions. Protein concentrations were
estimated by Bradford reagents and equal amounts of
total proteins were separated on a 10% SDS-PAGE gel.
The proteins were transferred to nitrocellulose membrane
(BioRad, Hercules, CA) using the BioRad Blotting System
according to the manufacturer’s instructions. Staining with
Ponceau Red was done to confirm equal transfer of protein
in all lanes. Blots were blocked for 2 hours in 5% non-fat
milk and incubated with antiserum overnight at 4°C. After
washing three times in TBST, the blots were incubated
with the second conjugated antibody. The blots were
detected by Supersignal West Pico Chemiluminescent Kit
(Pierce). The membranes were then stripped and re-probed
for either β-actin or GAPDH as internal controls.

Immunostaining
Cells were grown on glass cover slides, fixed with
3.5% formaldehyde for 15 minutes, and permeabilized
with 0.02% NP-40 for 1 minute. After blocking with
5% goat serum for 1 hour, cells were incubated with
anti-AR antibodies (N20) for 2 hours. The slides were
then incubated in donkey anti-rabbit immunoglobin G
conjugated with Alexa Fluor 594 for 2 hours. One drop
of mounting medium (Fisher Scientific) was added onto
each slide and the images were visualized by conventional
microscopy.

Immunoprecipitation
Immunoprecipitation was done with cell lysates
containing about 400 µg of protein in 100 µL. The
lysates were pre-cleared with 25 µL of Pierce Protein
A/G Magnetic Beads for 2 h. Lysate + beads were placed
on the magnet for 2 min. The pre-cleared lysate was
removed from the beads and 1µg of antibody was added.
All samples (lysate + antibody) were incubated at 4°C
overnight. The following day 100 µL of Pierce Protein
A/G Magnetic Beads were added to the lysate + antibody,
vortexed and rotated at 4°C for 2 h. All samples were
placed on the magnet for 2 min and unbound lysate was
removed. Beads were washed 3× with 100 µL washing
buffer, vortexed and spun briefly before being placed on
the magnet for 2 min. Proteins bound on the beads were
eluted with 20 µL of 2× SDS sample buffer, and then
boiled for 5 min before electrophoresis.

Transient transfection
ARV7 expressing plasmid was transiently
transfected into PC3 cells using Lipofectamine 2000
reagent according to the manufacturer’s instructions
(Invitrogen). Transfected cells were allowed to recover
for 6 hours before replacing with regular growth media
followed by specific treatments for designated time
periods. Cells were harvested and used for specific assays.
All experiments were conducted in triplicate.

RNA isolation, RT-PCR and qPCR
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Total RNA was isolated using the RNeasy mini kit
(Qiagen) according to the manufacturer’s specifications.
Total RNA from each sample was reverse-transcribed with
random primers using a StrataScript reverse transcriptase
kit (Stratagene) followed by either semi-quantitative
or real-time PCR. Our standard PCR procedures are as
follows: in a 25 µl reaction, DNA was denatured at 94°C
for 2 min and followed by 30 cycles of 94°C for 45sec;
62°C for 45sec and 72°C for 45sec. After the last cycle,
reactions were incubated for an additional 5 min at 72°C
to ensure that all DNA strands were extended to the ends.
PCR products were separated by electrophoresis on 1%
agarose gel and visualized under UV light. The intensities
of DNA bands were estimated by the Image-J program.
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